Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 3 | 4 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 8 | 8 |
| 2009 | 2 | 11 | 13 |
| 2010 | 3 | 13 | 16 |
| 2011 | 1 | 18 | 19 |
| 2012 | 2 | 16 | 18 |
| 2013 | 3 | 21 | 24 |
| 2014 | 0 | 36 | 36 |
| 2015 | 0 | 31 | 31 |
| 2016 | 0 | 44 | 44 |
| 2017 | 2 | 43 | 45 |
| 2018 | 3 | 35 | 38 |
| 2019 | 2 | 46 | 48 |
| 2020 | 1 | 41 | 42 |
| 2021 | 5 | 31 | 36 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 3 | 3 |
| 2024 | 3 | 24 | 27 |
| 2025 | 0 | 29 | 29 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength. Cancer Immunol Res. 2025 Oct 01; 13(10):1576-1590.
-
Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. Cancer Immunol Res. 2025 Oct 01; 13(10):1591-1608.
-
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy. Cancer Res. 2025 Oct 01; 85(19):3737-3751.
-
Central memory-enriched V?9Vd2 ?d T cells via TGF-? expansion demonstrate enhanced in vivo efficacy against metastatic osteosarcoma. Front Immunol. 2025; 16:1657760.
-
B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response. Clin Cancer Res. 2025 Sep 02; 31(17):3754-3770.
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
-
IL-7 armed binary CAR T cell strategy to augment potency against solid tumors. Front Immunol. 2025; 16:1618404.
-
Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control. J Immunother Cancer. 2025 Jul 23; 13(7).
-
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. J Clin Invest. 2025 Sep 16; 135(18).
-
An old spice with new tricks: Curcumin targets adenoma and colorectal cancer stem-like cells associated with poor survival outcomes. Cancer Lett. 2025 Oct 01; 629:217885.